5-氨基-2,4-二氟苯甲酸甲酯 | 125568-73-2

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 酯类氨基酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-氨基-2,4-二氟苯甲酸甲酯
• 英文名称: methyl 5-amino-2,4-difluorobenzoate
• CAS: 125568-73-2
• 化学式: C₈H₇F₂NO₂
• mdl: MFCD09396710
• 分子量: 187.146
• InChiKey: HHAREYZKVHGBEP-UHFFFAOYSA-N

物化性质

• 沸点：
  284.0±40.0 °C(Predicted)
• 密度：
  1.355±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2922499990
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  | 2-8°C |

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl 5-amino-2,4-difluorobenzoate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 5-amino-2,4-difluorobenzoate
CAS number: 125568-73-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H7F2NO2
Molecular weight: 187.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-氨基-2,4-二氟苯甲酸甲酯 在 N,N'-羰基二咪唑 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 (R)-tert-butyl 4-(3-(2,4-difluoro-5-(methoxycarbonyl)phenyl)-1-(2-hydroxy-1-phenylethyl)ureido)piperidine-1-carboxylate
  参考文献：
  名称：

  Alkali Carbonate Effects onN-(2-Hydroxyethyl)ureaCyclization: Application to a 2-Imidazolidinone Scale-Up

  摘要：

  An imidazolidinone intermediate (3) used in the synthesis of novel HIV-entry inhibitors was prepared on multihundred gram scales in four steps and 40% overall yield. The penultimate step in the synthesis involved regioselective N-cyclization of N-(2-hydroxylethyl)urea (11) by in situ activation of the terminal hydroxyl group with p-TsCl in the presence of base. The ratio of N-cyclized to O-cyclized products followed a group IA periodic trend relative to the alkali carbonate base employed. The use of Cs2CO3 as base effected the desired N-cyclization with a high degree of regiocontrol (>98%).

  DOI：

  10.1002/jhet.1648
• 作为产物：
  描述：

  2,4-二氟-5-硝基苯甲酸甲酯 在 铁粉 、 溶剂黄146 作用下， 以 水 为溶剂， 反应 1.5h， 以96%的产率得到5-氨基-2,4-二氟苯甲酸甲酯
  参考文献：
  名称：

  [EN] CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS
  [FR] ANTAGONISTES DE CCR5 COMME AGENTS THÉRAPEUTIQUES

  摘要：

  本发明涉及在治疗与CCR5相关的疾病和紊乱中有用的化合物，例如，在抑制HIV复制、预防或治疗HIV感染以及治疗由此导致的获得性免疫缺陷综合症（AIDS）方面有用的化合物。

  公开号：

  WO2009075960A1

文献信息

• 腺苷受体拮抗剂
  申请人：厦门宝太生物科技股份有限公司

  公开号：CN112028891B

  公开（公告）日：2022-07-05

  本发明提供了一种式(I)化合物及其药物组合物。本发明的式(I)化合物可用作腺苷受体抑制剂，尤其是A2A和/或A2B抑制剂，例如可以用于预防或治疗与A2A和/或A2B活性或表达量相关的疾病。
• [EN] 2-OXO-THIAZOLE DERIVATIVES AS A2A INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS<br/>[FR] DÉRIVÉS DE 2-OXO-THIAZOLE EN TANT QU'INHIBITEURS DE A2A ET COMPOSÉS DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE CANCERS
  申请人：ITEOS THERAPEUTICS

  公开号：WO2018178338A1

  公开（公告）日：2018-10-04

  The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof. The invention further relates to the use of the compounds of Formula (I) as A2A inhibitors. The invention also relates to the use of the compounds of Formula (I) for the treatment and/or prevention of cancer. The invention also relates to a process for manufacturing compounds of Formula (I).

  本发明涉及式（I）的化合物或其药用可接受的盐或溶剂化合物。该发明进一步涉及将式（I）的化合物用作A2A抑制剂。该发明还涉及将式（I）的化合物用于治疗和/或预防癌症。该发明还涉及一种制造式（I）化合物的方法。
• NON BRAIN PENETRANT A2A INHIBITORS AND METHODS FOR USE IN THE TREATMENT OF CANCERS
  申请人：ITEOS THERAPEUTICS S.A.

  公开号：US20200102319A1

  公开（公告）日：2020-04-02

  The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention further relates to the use of the compounds of Formula (I) as A2A inhibitors. The invention also relates to the use of the compounds of Formula (I) for the treatment and/or prevention of proliferative disorders, including cancers.

  本发明涉及式（I）的化合物或其药用可接受盐。该发明进一步涉及将式（I）的化合物用作A2A抑制剂。该发明还涉及将式（I）的化合物用于治疗和/或预防增殖性疾病，包括癌症。
• 一种多环类化合物、其制备方法及应用
  申请人：苏州信诺维医药科技有限公司

  公开号：CN111303128B

  公开（公告）日：2020-10-27

  本发明公开了一种多环类化合物、其制备方法及应用。本申请提供了一种如式I所示的多环类化合物或其药学上可接受的盐；该化合物对CDK7的抑制效果较佳。
• From hit to lead: Structure-based discovery of naphthalene-1-sulfonamide derivatives as potent and selective inhibitors of fatty acid binding protein 4
  作者：Ding-Ding Gao、Hui-Xia Dou、Hai-Xia Su、Ming-Ming Zhang、Ting Wang、Qiu-Feng Liu、Hai-Yan Cai、Hai-Peng Ding、Zhuo Yang、Wei-Liang Zhu、Ye-Chun Xu、He-Yao Wang、Ying-Xia Li

  DOI：10.1016/j.ejmech.2018.05.007

  日期：2018.6

  potent and selective FABP4 inhibitors by applying a structure-based design strategy. The binding affinities of compounds 16dk, 16do and 16du to FABP4, at the molecular level, are equivalent to or even better than that of BMS309403. The X-ray crystallography complemented by the isothermal titration calorimetry studies revealed the binding mode of this series of inhibitors and the pivotal network of

  脂肪酸结合蛋白4（FABP4）在代谢和炎症过程中起关键作用，因此是免疫代谢疾病（例如糖尿病和动脉粥样硬化）的潜在治疗靶标。在这里，我们报告了通过应用基于结构的设计策略，将萘-1-磺酰胺衍生物鉴定为新型，有效和选择性的FABP4抑制剂。化合物16dk，16do和16du的结合亲和力在分子水平上，对FABP4的抗性等于或什至优于BMS309403。X射线晶体学等温滴定量热法研究的补充，揭示了这一系列抑制剂的结合模式以及FABP4结合口袋中有序水分子的关键网络。此外，化合物16dk和16do在肝微粒体中表现出良好的代谢稳定性。进一步的广泛体内研究表明，通过降低空腹血糖和血清脂质水平，增强胰岛素敏感性以及减轻肥胖糖尿病患者的肝脂肪变性，dbd和16do可以显着改善葡萄糖和脂质代谢（db / db） 老鼠。